Skip Navigation


Human Molecular Genetics Advance Access originally published online on October 25, 2005
Human Molecular Genetics 2005 14(23):3685-3695; doi:10.1093/hmg/ddi400
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
14/23/3685    most recent
ddi400v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bonneick, S.
Right arrow Articles by Suter, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonneick, S.
Right arrow Articles by Suter, U.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

An animal model for Charcot–Marie–Tooth disease type 4B1

Sonja Bonneick1, Matthias Boentert2, Philipp Berger1, Suzana Atanasoski1, Ned Mantei1, Carsten Wessig3, Klaus V. Toyka3, Peter Young2 and Ueli Suter1,*

1Institute of Cell Biology, Department of Biology, Swiss Federal Institute of Technology, ETH-Hönggerberg, CH-8093 Zurich, Switzerland, 2Department of Neurology, University of Münster, Münster, Germany and 3Department of Neurology, Julius Maximilians-Universität Würzburg, Würzburg, Germany

* To whom correspondence should be addressed. Tel: +41 446333432; Fax: +41 446331190; Email: usuter{at}cell.biol.ethz.ch

Received August 23, 2005; Accepted October 14, 2005

Charcot–Marie–Tooth disease (CMT) comprises a family of clinically and genetically very heterogeneous hereditary peripheral neuropathies and is one of the most common inherited neurological disorders. We have generated a mouse model for CMT type 4B1 using embryonic stem cell technology. To this end, we introduced a stop codon into the Mtmr2 locus within exon 9, at the position encoding amino acid 276 of the MTMR2 protein (E276X). Concomitantly, we have deleted the chromosomal region immediately downstream of the stop codon up to within exon 13. The resulting allele closely mimics the mutation found in a Saudi Arabian CMT4B1 patient. Animals homozygous for the mutation showed various degrees of complex myelin infoldings and outfoldings exclusively in peripheral nerves, in agreement with CMT4B1 genetics and pathology. Mainly, paranodal regions of the myelin sheath were affected, with a high degree of quantitative and qualitative variability between individuals. This pathology was progressive with age, and axonal damage was occasionally observed. Distal nerve regions were more affected than proximal parts, in line with the distribution in CMT. However, we found no significant electrophysiological changes, even in aged (16-month-old) mice, suggesting that myelin infoldings and outfoldings per se are not invariably associated with detectable electrophysiological abnormalities. Our animal model provides a basis for future detailed molecular and cellular studies on the underlying disease mechanisms in CMT4B1. Such an analysis will reveal how the disease develops, in particular, the enigmatic myelin infoldings and outfoldings as well as axonal damage, and provide mechanistic insights that may aid in the development of potential therapeutic approaches.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
F. L. Robinson, I. R. Niesman, K. K. Beiswenger, and J. E. Dixon
Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice
PNAS, March 25, 2008; 105(12): 4916 - 4921.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. Tersar, M. Boentert, P. Berger, S. Bonneick, C. Wessig, K. V. Toyka, P. Young, and U. Suter
Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2
Hum. Mol. Genet., December 15, 2007; 16(24): 2991 - 3001.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, S. N. Zolov, C. Y. Chow, S. G. Slutsky, S. C. Richardson, R. C. Piper, B. Yang, J. J. Nau, R. J. Westrick, S. J. Morrison, et al.
Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice
PNAS, October 30, 2007; 104(44): 17518 - 17523.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
P. Berger, I. Berger, C. Schaffitzel, K. Tersar, B. Volkmer, and U. Suter
Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2
Hum. Mol. Genet., February 15, 2006; 15(4): 569 - 579.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.